Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 47Lymphoid 27Myeloid 11Sarcoma 1Classical hematology 1

Conditions

Sarcoma, Myeloid 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Blast Crisis 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 15Doxorubicin 14pembrolizumab 12X-Rays 12Radiation 12Radiotherapy 10Temozolomide 9Phantoms, Imaging 9Vincristine 7Irinotecan 7Nivolumab 6Ifosfamide 6atezolizumab 5Gemcitabine 5palbociclib 4liposomal doxorubicin 4fludarabine 4cemiplimab 4cabozantinib 4Immunoglobulin G 4Imatinib Mesylate 4Etoposide 4Dactinomycin 4Carboplatin 4Bevacizumab 4selinexor 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytarabine × Sarcoma × 30 days × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡